Adenosine phosphate
Adenosine (adenosine phosphate) is a small molecule pharmaceutical. Adenosine phosphate was first approved as Adenocard on 1989-10-30. It is known to target transient receptor potential cation channel subfamily M member 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) |
Clinical
Clinical Trials
466 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 33 | 50 | 25 | 1 | 13 | 108 |
| Leukemia | D007938 | — | C95 | 34 | 54 | 7 | 1 | 1 | 77 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 22 | 38 | 4 | 1 | — | 55 |
| Coronary artery disease | D003324 | — | I25.1 | 3 | 1 | 4 | 1 | 4 | 12 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 3 | 1 | 1 | 4 | 10 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | 1 | 2 | 1 | 3 | 7 |
| Coronary disease | D003327 | — | — | 1 | 1 | 2 | 1 | 1 | 5 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | 1 | 1 | 2 | 1 | 5 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | 2 | 1 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 1 | 1 | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 30 | 61 | 7 | — | 1 | 86 |
| Myelodysplastic syndromes | D009190 | — | D46 | 26 | 43 | 4 | — | — | 59 |
| Neoplasms | D009369 | — | C80 | 19 | 15 | 1 | — | 1 | 30 |
| Myeloid leukemia | D007951 | — | C92 | 9 | 18 | 3 | — | 1 | 26 |
| Lymphoma | D008223 | — | C85.9 | 9 | 17 | 1 | — | — | 20 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 5 | 9 | 1 | — | — | 13 |
| Preleukemia | D011289 | — | — | 8 | 9 | 1 | — | — | 12 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | 4 | 7 | 1 | — | — | 10 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 7 | 1 | — | — | 10 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 4 | 4 | 1 | — | — | 8 |
Show 42 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 10 | 17 | — | — | — | 22 |
| Hematologic neoplasms | D019337 | — | — | 10 | 8 | — | — | 1 | 17 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 5 | 11 | — | — | — | 15 |
| Hodgkin disease | D006689 | — | C81 | 8 | 10 | — | — | — | 14 |
| Multiple myeloma | D009101 | — | C90.0 | 5 | 10 | — | — | — | 13 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 7 | — | — | 2 | 13 |
| Recurrence | D012008 | — | — | 6 | 7 | — | — | — | 13 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 8 | 7 | — | — | — | 12 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 5 | — | — | — | 8 |
| Colorectal neoplasms | D015179 | — | — | 3 | 6 | — | — | 1 | 8 |
Show 128 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | — | — | — | 2 | 3 |
| Chronic cough | D000096822 | — | R05.3 | 1 | — | — | — | 1 | 2 |
| Magnetic resonance imaging | D008279 | — | — | 1 | — | — | — | 1 | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
| Thrombocytosis | D013922 | — | D75.83 | 1 | — | — | — | — | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | — | — | — | — | 1 |
| Neutropenia | D009503 | — | D70 | 1 | — | — | — | — | 1 |
| Bone marrow diseases | D001855 | — | — | 1 | — | — | — | — | 1 |
| Bone marrow transplantation | D016026 | — | — | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 3 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 3 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 2 | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 2 | 2 |
| Craniofacial abnormalities | D019465 | — | — | — | — | — | — | 2 | 2 |
| Arthrogryposis | D001176 | EFO_0003857 | Q74.3 | — | — | — | — | 2 | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | — | 2 | 2 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | — | — | 2 | 2 |
Show 76 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Adenosine phosphate |
| INN | adenosine phosphate |
| Description | Adenosine 5'-monophosphate is a purine ribonucleoside 5'-monophosphate having adenine as the nucleobase. It has a role as an EC 3.1.3.11 (fructose-bisphosphatase) inhibitor, an EC 3.1.3.1 (alkaline phosphatase) inhibitor, an adenosine A1 receptor agonist, a nutraceutical, a micronutrient, a fundamental metabolite and a cofactor. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-monophosphate. It is a conjugate base of an adenosine 5'-monophosphate(1+). It is a conjugate acid of an adenosine 5'-monophosphate(2-). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 61-19-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL752 |
| ChEBI ID | 16027 |
| PubChem CID | 6083 |
| DrugBank | DB00131 |
| UNII ID | 415SHH325A (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,933 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
410 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use